Wells Fargo downgraded iTeos Therapeutics (ITOS) to Equal Weight from Overweight with a $12 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics Stock (ITOS) Booms 24% as it Winds Down and Sells Cancer Treatments
- iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision
- iTeos Therapeutics downgraded to Neutral from Outperform at Wedbush
- iTeos Therapeutics Announces Strategic Wind Down Plan
- iTeos Therapeutics announces intention to wind down operations